Vima Therapeutics is gearing up to launch a Phase 2 clinical trial this year to evaluate VIM0423, its potential first-in-class once-daily oral therapy for dystonia, or abnormal muscle tone, associated with Parkinson’s disease. Meanwhile, the first participant has been dosed in Stride Dystonia, a Phase 2…
News
Casma Therapeutics has been awarded $7.6 million from The Michael J. Fox Foundation (MJFF) to support the preclinical development of its CSM-101 therapy candidate for Parkinson’s disease. The funding includes a $2.1 million grant under the Targets to Therapies Initiative, which will be used for helping…
The integration of Kneu Health’s smartphone-based platform into Cedars-Sinai’s Parkinson’s care program enabled ongoing symptom monitoring and revealed the need for earlier intervention in 79% of encounters. According to the company, clinicians reported that the added insight helped care teams monitor treatment responses and inform more timely, personalized…
Immunis said it entered into an exclusive deal with Toray for the rights to develop and commercialize a potential treatment for dyskinesia, the involuntary movements associated with long-term use of levodopa in people with Parkinson’s disease, and has submitted an application to the U.S. Food…
Oncodesign Precision Medicine (OPM) has been awarded a $6.92 million research grant from The Michael J. Fox Foundation (MJFF) to prepare its LRRK2 inhibitor, OPM-201, for a clinical study in people with early Parkinson’s disease. The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange…
Regulators in the U.S. and China have granted Xellsmart permission to start clinical testing of its experimental stem cell therapy in people with multiple system atrophy-Parkinsonian type (MSA-P). This is the fourth clinical trial program for Xellsmart’s stem cell therapy platform to have received regulatory clearance from both the…
Japan’s Ministry of Health, Labour and Welfare has granted conditional approval to Amchepry, Sumitomo Pharma’s stem cell-derived therapy designed to replace dopamine-producing nerve cells, for people with Parkinson’s disease who do not respond adequately to existing treatments such as levodopa. The approval was based on results from a …
A fully implanted brain device can identify when people with Parkinson’s disease are walking during their everyday lives, according to a new study from the University of California, San Francisco (UCSF). By recording neural activity from movement-related brain regions while patients went about their normal routines at home, researchers…
Impaired cellular energy may interfere with how dopamine — the key chemical messenger that is in short supply in Parkinson’s disease — is packaged and handled inside nerve cells, a new study has found. According to the researchers, such disruptions, and a resulting energy shortage, may promote the formation…
The Silvi Foundation has officially launched as a nonprofit organization dedicated to advancing research into Parkinson’s disease and other neurodegenerative conditions. As its first initiative, the newly established foundation has awarded a $100,000 grant to the Institute for Neurodegenerative Diseases (IND) to support research on blood-based biomarkers…
Recent Posts
- Parkinson’s changed my uncle’s daily life, but his personality remained
- Developer targeting abnormal muscle tone in Parkinson’s with its VIM0423
- MJFF grants totaling $7.6M will help Casma develop Parkinson’s therapy
- Planning is key when traveling with Parkinson’s disease
- I’m an optimist, but sometimes Parkinson’s fatigue is too much